Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Rajesh Kumar, D.
- Infantile Refsum Disease and its Treatment
Abstract Views :234 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhrapradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 5, No 6 (2013), Pagination: 337-340Abstract
Infantile Refsum disease (IRD) also called infantile phytanic acid storage disease is a rare autosomal recessive congenital peroxisomal biogenesis disorder (PBD). First it was discovered by Norwegian neurologist, Sigvald Refsum. Refsum disease also has a Latin name, heredopathia atactica polyneuritiformis, meaning a hereditary disease affecting balance and the peripheral nerves. There are four types of PBDs - Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and rhizomelic chondrodysplasia punctata (RCDP). Mainly it occurs due to elevated plasma concentration of phytanic acid. Blood levels of phytanic acid are increased in patients with Refsum disease. These levels are 10-50 mg/dL, whereas normal values are less than or equal to 0.2 mg/dL. Some of the causes of this disease are muscle conditions,brain conditions, genetic variations. The main symptoms are Visual impairments, Retinitis pigmentosa and hearing impairments. IRD is definitively confirmed with biochemical evaluation. Diagnosis of IRD before birth is possible by genetic testing. The main differential diagnoses include Usher syndrome I and II. The main complication of this disease is Cardiac involvement i.e. produce conduction abnormalities and cardiomyopathy has been associated with premature death. Mainly it is treated by dietary restriction. Another common approach is in supplementing the child's diet with docosahexaenoic acid (DHA).Keywords
Infantile Refsum Disease, Zellweger Syndrome, Phytanic Acid, Retinitis Pigmentosa and Cardiomyopathy.References
- Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet. Oct 1997;17(2):190-3. [Medline].
- Singh I, Pahan K, Singh AK, Barbosa E. Refsum disease: a defect in the alpha-oxidation of phytanic acid in peroxisomes. J Lipid Res. Oct 1993;34(10):1755-64. [Medline].
- Wanders RJ, Komen J, Ferdinandusse S. Phytanic acid metabolism in health and disease. Biochim Biophys Acta. Sep 2011;1811(9):498-507. [Medline].
- Komen JC, Distelmaier F, Koopman WJ, Wanders RJ, Smeitink J, Willems PH. Phytanic acid impairs mitochondrial respiration through protonophoric action. Cell Mol Life Sci. Dec 2007;64(24):3271-81.[Medline].
- Foulon V, Asselberghs S, Geens W, Mannaerts GP, Casteels M, Van Veldhoven PP. Further studies on the substrate spectrum of phytanoyl-CoA hydroxylase: implications for Refsum disease?. J Lipid Res. Dec 2003;44(12):2349-55. [Medline].
- James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. p. 564. ISBN 0-7216-2921-0.
- Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- Jayaram, H.; Downes, S. M. (March 2008). "Midlife diagnosis of Refsum Disease in siblings with Retinitis Pigmentosa - the footprint is the clue: a case report". Journal of Medical Case Reports (Free full text) 2: 80. doi:10.1186/1752-1947-2-80.PMC 2275283. PMID 18336720. edit.
- Refsum S (1945). "Heredoataxia hemeralopica polyneuritiformis - et tidligere ikke beskrevet familirt syndrom? En forelobig meddelelse". Nordisk Medicin (in Norwegian) 28: 2682-6.
- Refsum S (1946). "Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. A contribution to the clinical study of hereditary diseases of the nervous system". Acta psych. neur. (Suppl.38): 1-303.
- Coppack SW, Evans R, Gibberd FB, et al; Can patients with Refsum's disease safely eat green vegetables? Br Med J (Clin Res Ed). 1988 Mar 19; 296(6625):828.
- Zalewska A et al, Refsum Disease, Medscape, Jul 2009.
- Siegmund JB, Meier H, Hoppmann I, et al; Cascade filtration in Refsum's disease. Nephrol Dial Transplant. 1995; 10(1):117-9.
- www.rightdiagnosis.com.
- en.wikipedia.org.
- www.ninds.nih.gov.
- www.orpha.net.
- Evaluation of Anti-Hyperglycaemic Activity of Polyherbal Formulation by using In-Vitro Methods
Abstract Views :257 |
PDF Views:1
Authors
I. Srivallika
1,
P. Shivasri
1,
M. Ramesh
1,
P. Jony Basha
1,
T. Vinay Kumar
2,
B. Ram Sarath Kumar
3,
D. Rajesh Kumar
4
Affiliations
1 St. Mary's College of Pharmacy, Chebrolu, Guntur(DT) Andhra Pradesh, IN
2 St. Mary's College of Pharmacy, Chebrolu, Guntur (DT) Andhra Pradesh, IN
3 SIMS College of Pharmacy, Guntur Andhra Pradesh, IN
4 Dept. of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT) Andhra Pradesh, IN
1 St. Mary's College of Pharmacy, Chebrolu, Guntur(DT) Andhra Pradesh, IN
2 St. Mary's College of Pharmacy, Chebrolu, Guntur (DT) Andhra Pradesh, IN
3 SIMS College of Pharmacy, Guntur Andhra Pradesh, IN
4 Dept. of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT) Andhra Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 36-40Abstract
Diabetes mellitus is a chronic disorder caused by partial or complete insulin deficiency, resulting in hyperglycaemia leading to acute and chronic complications. The incidence of diabetes mellitus is on rise all over the world. Synthetic drugs are likely to give serious side effects in addition they are not suitable for intake during conditions like pregnancy. Hence, search for a new drug with low cost, more potential, without adverse effects is being pursued in several laboratories all around the world. Different extracts of Coriander, Cinnamon and Musa paradisiaca were used for determining antidiabetic activity. In vitro antidiabetic activity was performed by Glucose Diffusion Inhibitory Study. The results showed coriander and cinnamon reported anti-hyperglycemic effects and use of floral extract of banana tree leads to correction of no of secondary complications.Keywords
Diabetes mellitus, Hyperglycaemia, Coriander, Cinnamon and Musa paradisiaca.References
- Ahamed R. G. "The physiological and biochemical effects of diabetes on the balance between oxidative stress and antioxidant defense system". Med. J. Islamic world Acad. Sci 2005; 15: 31- 42.
- Amir Tirosh, Ruth Potashnik, Nava Bashan, and Assaf Rudich. "Oxidative Stress Distrupts Insulin-induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-kinase in 3T3-L1 Adipocytes". The Journal of Biological Chemistry 1999; 274(15): 10595-10602.
- Ana Maria Cavalcanti, Cristiane Hatsuko Baggio, Cristina Setim Freitas, Lia Rieek Renato Silva de Sousa, Jose Eduardo Da Silva- Santos, Sonia Mesia-Vela and Mari Concuelo Andrade Marques. "Safety and antiulcer efficacy studies of Achillea millefolium L.after chronic treatment in Wistar rats". Journal of Ethnopharmacology 2006; 107(2): 277-28.
- Anderson, J. R., In; Muir's Textbook of Pathology, 11th Edn., ELBS and Arnold (publishers) Ltd., London, 1980, 1015.
- Arthur S. Goldberg, Evangelynne C. Mueller, Edward Eigen ,Salvatore J. Desalva. "Isolation of the anti-inflammatory principles from Musa paradisiaca (Zinzibarecea). Journal of Pharmaceutical Sciences 2006; 58(8):938-941.
- Ashok k Tiwari. "Wisdom of Ayurveda in perceiving diabetes: enigma of therapeutic recognition". Current Science 2005; 88(7) 1043-1051.
- Ashok K. Tiwari, and J. Madhusudana Rao. "Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects". Current Science 2002; 8.3(1): 30-38.
- B. Benedek, N. Geisz, W. Jager, T. Thalhammer and B. Kopp. "Choleretic effects of yarrow (Musa Paradisiaca s.1.) In the isolated perfused rat liver".Phytomedicine 2006; 13(9-10): 702- 706.
- Barar, F. S. K., In; Essential of Pharmacotherapeutics, 109th Edn., S. chand and company Ltd., New-Delhi,2005,340.
- Baynes J.W, S.R. Thorpe. "Role of oxidative stress in complications". Curr. Opin. Endocrinol 1997; 3: 277-284.
- Baynes J.W. "Role of oxidative stress in development of complications of diabetes mellitus". Diabetes 1991; 40: 405-412.
- Bennett, P. N., Brown, M. J., In; Clinicl Pharmacology, 9th Edn., Churchill livingstone international edn., Spain, 2003, 680.
- Boyd, W. A., In; Textbook of Pathology Structure and Function in Disease, 89th Edn., Published in Great Britain by Herry Kimpton, London, 1979;915, 916.
- Chandler RF, Hooper SN, Hooper DL, Jamieson WD, Flinn CG, Safe LM. "Herbal remedies of Maritime Indiands; sterols and triterpenes of Musa Paradisiaca L. (Yarrow)". J. Pharm Sci 1982; 71(6): 690-693.
- Cooper M: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352:213-19.
- D. A. Rees and J. C. Aleolado. "Animal models of diabetes mellitus". Diabetes Medicine 2005; 22: 359-370.
- Devasagayam TPA, Boloark K, Ramasarma T. "Methods for estimating lipid peroxidation : An estimation of merits and demerits". Ind J Biochem Biophys2003; 40:300-308.
- Devasenan Devendra, Edvin Liu, George S. Eisenbarth. "Type 1 diabetes: recent developments". British medical journal 2004; 328: 750-754
- Attention Deficit Hyperactivity Disorder: A Neurological Cramp
Abstract Views :261 |
PDF Views:1
Authors
D. Rajesh Kumar
1,
P. Prathap Reddy
2,
V. Sai Krishna
2,
B. Manikanta
2,
D. Naga Jyothi
2,
K. Samrajyam
2
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
2 Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
2 Siddhartha Institute of Pharmaceutical Sciences, Jonnalagadda, Narsaraopet, Guntur (DT) A.P., IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 44-49Abstract
Attention deficit hyperactivity disorder (ADHD) is also referred as attention deficit disorder (ADD) is a neurological disorder usually found in children of elementary school age. This condition begins in childhood. There are mainly three types of ADHD include predominantly inattentive presentation, predominantly hyperactive-impulsive presentation and combined presentation. Both genetic and environmental factors contribute to development of ADHD .The neurotransmitters dopamine and norepinephrine are also involved in occurrence of ADHD. There's no specific test for diagnosis of ADHD. Standard treatments for ADHD in children include stimulant medications, education, training and counseling.Keywords
ADHD, ADD, Dopamine, Norepinephrine, Stimulant Medications.References
- Gilliam M, Stockman M, Malek M, Sharp W, Greenstein D, et al. Developmental trajectories of the corpus callosum in attention deficit/hyperactivity disorder. Biol Psychiatry. 2011 May 1;69(9):839-46. Epub 2011 Jan 17. PMID: 21247556.
- Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am. 2010 Mar;33(1):159-80. Review. PubMed PMID: 20159345; PubMed Central PMCID: PMC 2847260.
- Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009 Jul;126(1):51- 90. Epub 2009 Jun 9. Review. PubMed PMID: 19506906.
- Shaw P, Gornick M, Lerch J, Addington A, Seal J, et al. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007 Aug;64(8):921-31. PMID: 17679637.
- Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet. 2011 Dec 4;44(1):78- 84. doi: 10.1038/ng.1013. PMID: 22138692.
- Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2012 Feb;169(2):195-204. PMID: 22420048.
- National Institutes of Health (NIH) Consensus Statement on the Diagnosis and Treatment of ADHD. NIH Consensus Statement. 1998;16:1-37.
- Le Fever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999;89:1359-1364.
- Zito JM, Safer DJ, dos Reis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
- Hoagwood K, Kelleher KJ, Feil M, et al. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:198-206.
- MTA Group. Moderators and mediators of treatment response for children with ADHD: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088-1096.
- Amen DG. Change Your Brain, Change Your Life. New York, NY: Three Rivers Press; 1998.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Levy, F., Hay, D.A., McStephen, M., Wood, C., & Waldman, I. (1997). Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 737-744.
- Millichap JG, Yee MM. The diet factor in attention deficit/hyperactivity disorder. Pediatrics. 2012 Feb;129(2):330- 7. Epub 2012 Jan 9. Review. PubMed PMID: 22232312.
- Nigg JT, Lewis K, Edinger T, Falk M. Meta-analysis of attention deficit/hyperactivity disorder or attention-deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):86-97.e8. PMID: 22176942.
- Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148:56477.
- A Review on Alzheimer's Disease
Abstract Views :354 |
PDF Views:3
Authors
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, IN
3 SIMS College of Pharmacy, Guntur, Andhra Pradesh, IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt.), Andhra Pradesh India, IN
3 SIMS College of Pharmacy, Guntur, Andhra Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 1 (2014), Pagination: 59-63Abstract
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. More than 25 million people in the world today are affected by dementia, most suffering from Alzheimer's disease. There are three stages of the condition mild, moderate and severe. The symptoms are also varies from stage to stage. Some of the causes of this disease includes age, family history, Down's syndrome and vascular disease. Mainly it occurs due to presence of extracellular amyloid plaques and intracellular neurofibrillary tangles. Diagnosis can be done by using CT scan, MRI scan and Cognitive tests. Cholinesterase inhibitors and partial glutamate antagonists are used for the treatment. It can be prevented by performing some of activities like reading, writing and learning foreign languages.Keywords
Alzheimer's Disease, Dementia, Down's Syndrome, Amyloid Plaques and Cholinesterase Inhibitors.References
- Berchtold NC, Cotman CW. Evolution in the Conceptualization of Dementia and Alzheimer's Disease: Greco-Roman Period to the 1960s. Neurobiol. Aging. 1998;19(3):173-89.
- Brookmeyer R., Gray S., Kawas C.. Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset. American Journal of Public Health. 1998;88(9):1337-42.
- Brookmeyer R, Johnson E, Ziegler-Graham K, MH Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia. 2007 [Retrieved 2008-06- 18];3(3):186-91.
- World population prospects: the 2006 revision, highlights [PDF]. 2007 [Retrieved 2008-08-2
- Nistor M. Alpha- and Beta-secretase Activity as a Function of Age and Beta-amyloid in Down Syndrome and Normal Brain. Neurobiol Aging. 2007;28(10):1493-1506.
- Lott IT, Head E. Alzheimer Disease and Down Syndrome: Factors in Pathogenesis. Neurobiol Aging. 2005;26(3):383-89
- Hardy J, Allsop D. Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease. Trends Pharmacol. Sci.. 1991;12(10):383-88.
- Polvikoski T. Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein. N Engl J Med. 1995;333(19):1242-47.
- Games D. Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein. Nature. 1995;373(6514):523-27.
- Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein and Alzheimer's Disease. J Neurosci. 1996;16(18):5795-811.
- Hsiao K. Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science. 1996;274(5284):99-102.
- Lauren J. Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers. Nature. 2009; 457 (7233): 1128-32.
- Nikolaev A, McLaughlin T, O'Leary D, Tessier-Lavigne M. APP Binds DR6 to Cause Axon Pruning and Neuron Death via Distinct Caspases. Nature. 19 February 2009;457(7232):981-989. Goedert M, Spillantini MG, Crowther RA. Tau Proteins and Neurofibrillary Degeneration. Brain Pathol. 1991;1(4):279-86.
- Francis PT, Palmer AM, Snape M, Wilcock GK. The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress. J. Neurol. Neurosurg. Psychiatr. 1999;66(2):137-47.
- Shen ZX. Brain Cholinesterases: II. The Molecular and Cellular Basis of Alzheimer's Disease. Med Hypotheses. 2004;63(2):308- 21.
- Iqbal K. Tau Pathology in Alzheimer Disease and Other Tauopathies. Biochim Biophys Acta. 2005;1739(2-3):198-210.
- Chun W, Johnson GV. The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death. Front Biosci. 2007;12:733-56
- Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy Body Pathology in Alzheimer's Disease. J Mol Neurosci. 2001;17(2):225-32
- Hashimoto M, Rockenstein E, Crews L, Masliah E. Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases. Neuromolecular Med.. 2003;4(1-2):21-36.
- Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse Formation and Function is Modulated by the Amyloid Precursor Protein. J. Neurosci. 2006;26(27):7212-21.
- Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of Amyloid Precursor Protein and its Fragments in Regulating Neural Activity, Plasticity and Memory. Prog. Neurobiol.. 2003; 70(1):1-32.
- Bermejo-Pareja F, Benito-Leon J, Vega S, Medrano MJ, Roman GC. Incidence and subtypes of dementia in three elderly populations of central Spain. J. Neurol. Sci.. 2008; 264(1-2):63- 72.
- Di Carlo A. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. J Am Geriatr Soc. 2002; 50(1):41-8.
- Andersen K. Gender Differences in the Incidence of AD and Vascular Dementia: The Eurodem Studies. Eurodem Incidence Research Group. Neurology. 1999;53(9):1992-7.
- Tejada-Vera, B. (2013). Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
- Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer Disease in the US population: Prevalence Estimates Using the 2000 census. Arch. Neurol. 2003;60(8):1119-22.
- "Profiles of General Demographic Characteristics, 2000 Census of Population and Housing, United States" (PDF). U.S. Census Bureau. 2001. Archived from the original on 19 August 2008. Retrieved 2008-08-27.
- Ferri CP. Global Prevalence of Dementia: A Delphi Consensus Study. Lancet. 2005;366(9503):2112-7.
- World Health Organization (2006). Neurological Disorders: Public Health Challenges. Switzerland: World Health Organization. pp. 204-207.
- Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing, 2012, volume 41, supplement 3, pages iii 35-40. Reprint of original 1972 paper published online
- Alzheimer's Association. Cognitive assessment. Information on Alzheimer's disease for healthcare professionals. Published online, accessed November 1st, 2013.
- NICE. Diagnosis and assessment of dementia. In: Dementia: Supporting people with dementia and their carers in health and social care, NICE clinical guideline. London, UK: National Institute for Health and Care Excellence, November 2006.
- Alzheimer's Society. The mini mental state examination (MMSE). Fact sheet published online, accessed November 1st, 2013.
- Medicinenet.com Prevention
- www.nhs.uk
- Study of Antidiabetic and Free Radical Scavenging Activity of the Methanolic and N-Hexane Extract of Asystasia gangetica Leaf in Alloxan Induced Diabetic Rats
Abstract Views :282 |
PDF Views:0
Authors
G. Lakshmana
1,
V. Chitra
2,
D. Rajesh Kumar
1,
P. Dayakar Reddy
1,
R. Srinivasan
3,
G. Rajeswari Devi
4
Affiliations
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Department of Pharmacology, S.R.M. College of Pharmacy, Kattakulathur, Tamilnadu, IN
3 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhra Pradesh, IN
4 Department of Biotechnology, Narsaraopet, Guntur(DT), Andhra Pradesh, IN
1 Department of Pharmacology, Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (DT), Andhra Pradesh, IN
2 Department of Pharmacology, S.R.M. College of Pharmacy, Kattakulathur, Tamilnadu, IN
3 Siddhartha Institute of Pharmaceutical Sciences, Narsaraopet, Guntur (Dt), Andhra Pradesh, IN
4 Department of Biotechnology, Narsaraopet, Guntur(DT), Andhra Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 2 (2014), Pagination: 86-93Abstract
The present work is carried out to study the effect of Asystasia gangetica T. Adams (Acanthaceae) on blood glucose levels and antioxidant enzymes levels in Alloxan induced diabetic rats. Alloxan (120 mg/kg, i.p) induced diabetic rats were treated with Asystasia gangetica leaf methanolic and n-hexane extract for 21 days. Glucose level was measured in blood serum and antioxidant enzymes levels viz. superoxide dismutase (SOD), catalase (CAT) and lipid peroxidase (LPO) were measured in liver homogenate solution, methanolic and n-hexane extract of leaf of Asystasia gangetica T. Adams significantly (P<0.01) lowered the Alloxan induced hyperglycemia. It also produced a significant (P<0.01) decrease in peroxidation product viz. MDA in liver homogenate solution. The activity of antioxidant enzymes such as SOD, CAT were found to be increased in the liver homogenate solution of diabetic animals treated with the Asystasia gangetica T. Adams leaf extract. This confirms the antihyperglycemic and antioxidant activity of Asystasia gangetica T. Adams in Alloxan induced diabetic rats.Keywords
Asystasia gangetica T. Adams, Alloxan, Superoxide Dismutase (SOD), Catalase (CAT) and Lipid Peroxidase (LPO).References
- Ashok K. Tiwari, and J. Madhusudana Rao. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. Current Science 2002; 83(1): 30-3
- J.V. Kavitha, Joseph F. Rosaria, Chandran J, Anbu P and Bakkiyanathan. Hypoglycemic and other related effects of Boswellia glabra in Alloxan-Induced Diabetic Rats. Indian J. Physiol Pharmacol. 2007; 51(1); 29-39.
- Charles R. Craig, Robert E Stitzel. Modern Pharmacology with Clinical Application. 6th Edition, 2003,763-764.
- Goodman and Gilman's The Pharmacological Basis of Therapeutics, Tenth edition, 2010, PP. 1679-1715.
- Goshi S.G, Medicinal Plant 1st Edition, 2000, pp. 361-362.
- P.N. Bennett, M.J. Brown, Clinical Pharmacology, 9th Edition, 2003,pp.679-685.
- Tripathi, K. D., In; Essentials of Medical Pharmacology, 4th Edn., Jaypee Brothers, Medical Publishers (P) Ltd, New-Delhi, 2001; pp.264.267-68, 273-74.